Clinical Efficacy of Bevacizumab Concomitant with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer

Zhang, Yu-Mei; Li, Yong-Qiang; Liu, Zhi-Hui; Liao, Xiao-Li; Liang, Rong; Lin, Yan; Yuan, Chun-Ling; Liao, Si-Na; Liang, Chao-Yong; Li, Qian; Li, Le-Qun

추천

검색

자료유형: 학술저널

저자정보: Zhang, Yu-Mei (The Affiliated Cancer Hospital of Guangxi Medical University) Li, Yong-Qiang (The Affiliated Cancer Hospital of Guangxi Medical University) Liu, Zhi-Hui (The Affiliated Cancer Hospital of Guangxi Medical University) Liao, Xiao-Li (The Affiliated Cancer Hospital of Guangxi Medical University) Liang, Rong (The Affiliated Cancer Hospital of Guangxi Medical University) Lin, Yan (The Affiliated Cancer Hospital of Guangxi Medical University) Yuan, Chun-Ling (The Affiliated Cancer Hospital of Guangxi Medical University) Liao, Si-Na (The Affiliated Cancer Hospital of Guangxi Medical University) Liang, Chao-Yong (The Affiliated Cancer Hospital of Guangxi Medical University) Li, Qian (The Affiliated Cancer Hospital of Guangxi Medical University) Li, Le-Qun (The Affiliated Cancer Hospital of Guangxi Medical University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제8호

발행연도: 2014.1

수록면: 3,447 - 3,450 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: To observe the clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). Materials and Methods: A total of 72 patients were randomly divided into a combination group (pemetrexed+bevacizumab, n=36) and a pemetrexed group (n=36) and assessed for disease control (CR+PR+SD) after 4-cycles of first-line GP chemotherapy (gemcitabine+cisplatin). Clinical efficacy, progression-free survival time (PFS), overall survival time (OS), overall response rate (ORR), disease control rate (DCR) and rate of adverse responses between two groups were observed and compared. Results: ORR and DCR were 27.8% and 83.4% in combination group, and 16.7% and 69.5% in the pemetrexed group, respectively, but there were no significant differences (P>0.05). PFS in combination group and pemetrexed group were 4.6 months and 3.9 months respectively (P=0.09), whereas OS in the combination group was 14 months, evidently higher than in the pemetrexed group (11 months, P=0.004). Adverse responses in both groups included high blood pressure, bleeding, thrombocytopenia, anemia, elevated transaminase, diarrhea, vomiting and proteinuria, but there were no significant differences (P>0.05). Conclusions: Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC.

#Bevacizumab #pemetrexed #combined treatment #non-small cell lung cancer

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요